GlassScriptPhysician profile
Lisa Graham
NPI 1386955623
$3,445.02
in general payments reported to CMS, 2019-2025
20 companies · $510 in 2025
The $510 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $709 · 2020: $632 · 2021: $361 · 2022: $609 · 2023: $253 · 2024: $371 · 2025: $510.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,013 · Education: $121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,012.95 |
| Education | $120.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $860.58 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $665.50 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $385.85 | 2019-2025 | Jascayd |
| Genzyme Corporation | $329.61 | 2020-2025 | |
| Genentech USA, INC. | $226.55 | 2019-2022 | |
| La Jolla Pharmaceutical Company | $165.29 | 2019-2022 | |
| Philips North America LLC | $152.62 | 2020-2021 | |
| Mylan Specialty L.P. | $122.55 | 2019-2024 | Yupelri |
| Inari Medical, INC. | $100.24 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $80.20 | 2022-2024 | Dupixent |
| Sanofi-Aventis U.S. LLC | $78.99 | 2025 | |
| Merck Sharp & Dohme LLC | $60.96 | 2025 | Zerbaxa |
| Insmed, INC. | $48.26 | 2024-2025 | Arikayce |
| Grifols USA, LLC | $40.62 | 2020-2021 | |
| Electromed, INC. | $37.95 | 2023-2024 | Smartvest |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $21.51 | 2025 | Yupelri |
| Abiomed | $18.37 | 2025 | |
| Pfizer INC. | $17.96 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $15.78 | 2024 | Opsumit, Uptravi |
| Shire North American Group INC | $15.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Graham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.